Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Clinical trial NCT06760260 · RECRUITING
Trial details
- NCT number
- NCT06760260
- Sponsor
- Hrain Biotechnology Co., Ltd.
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-26
- Primary completion
- 2025-12-31
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.